Skip to content

Psilocybin: all studies

Page 312 of 440: studies 3,111 to 3,120 of 4,392, newest first. Back to the psilocybin overview

Research

Psychedelics: Historical Context, Emerging Science, and Future Clinical Frontiers

Journal of Mental Health Disorders April 18, 2026 Vipul Janardan, Amit Khanna, Om Prakash et al.

Psychedelics a class of psychoactive compounds such as psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) are undergoing a scientific renaissance. Studies since 2020 have shown their therapeutic promise in mental health treatment. This Commentary synthesizes historical usage, current neuroscientific and clinical evidence, and explores ethical and regulatory frontiers for...

Psychedelics and Autism Therapy: A Review of Current Research and Future Directions

Current Issues in Molecular Biology April 18, 2026 Christopher S. Gondi, Manu Gnanamony, Tarun P. Gondi et al.

Autism Spectrum Disorder (ASD) is a lifelong condition marked by challenges in social communication and repetitive behaviors. Current treatments, primarily behavioral therapies, often fail to address the core symptoms. Recent research has explored the potential of psychedelics, such as LSD, psilocybin, and MDMA, as a new therapeutic approach. While these substances primarily modulate the...

DOI: 10.3390/cimb48040417 (opens in new tab) Neuroplasticity Glutamatergic Autism spectrum disorder Therapeutic approach +2

Producción de alcaloides en Psilocybe cubensis: aportes desde la bioquímica del Triptófanoy la sustentabilidad

CIENCIA EN DESARROLLO April 16, 2026 Brenda M. Delgado Melgarejo, Gerardo A. Caicedo

Esta revisión analiza cómo la suplementación con L-triptófano en el sustrato de cultivo de Psilocybe cubensis potencia la biosíntesis de psilocibina vía las enzimas PsiD, PsiH, PsiK y PsiM, alcanzando aumentos significativos en laconcentración alcaloide respecto a controles sin suplemento.La psilocibina después de ser ingerida se convierte en psilocina por un proceso de desfosforilación, que...

Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs

Journal of Psychopharmacology April 16, 2026 Jesse J. Norris 1 citation

Background: Little research investigates the role of rarely used drugs in criminal offending. Moreover, given research suggesting that psychedelics reduce criminal offending, more research is needed to further document connections between psychedelics and crime. Aim: This study examines the role of rarely used drugs in criminal behavior and extends previous research on psychedelics by...

DOI: 10.1177/02698811261436577 (opens in new tab) MDMA Substance use Criminal behavior Hallucinogen +5

Blinding Integrity in Psychedelic Randomized Clinical Trials

JAMA Psychiatry April 15, 2026 Diana Orsini, Sabrina Wong, Sara Di Luch et al. 4 citations

Importance: Psychedelic drugs possess acute psychoactive effects that can compromise blinding integrity in randomized clinical trials (RCTs). Functional unblinding, when participants or raters correctly identify treatment allocation based on subjective effects, may bias outcomes through expectancy effects, challenging the validity of efficacy estimates and regulatory acceptance. Objective: To...

DOI: 10.1001/jamapsychiatry.2026.0255 (opens in new tab) Blinding Randomized controlled trial Clinical trial Meta-analysis +4

Psychiatric treatment: breaking new ground?

The Brown University Child and Adolescent Behavior Letter April 13, 2026 David P. Lichtenstein

Excitement has built recently about new avenues for psychiatric treatment: psychedelic drugs such as Ketamine and psilocybin; trans‐cranial magnetic stimulation (TMS). We see the revival of older practices such as electro‐convulsive shock therapy (ECT) and therapeutic lesioning, and medicines borrowed from other fields, like GLP‐1s.

Persona y ambiente: una revisión narrativa sobre la importancia del contexto en la terapia asistida con psicodélicos

Vertex Revista Argentina de Psiquiatría April 10, 2026 Daniel Arroyo-Zúñiga, Javeth Calvo-Molina, José Manuel Rodríguez-arce

Este artículo presenta una revisión narrativa sobre las variables extrafarmacológicas que influyen en la terapia asistida con psicodélicos (TAPs). A partir del análisis de literatura reciente, se destaca la importancia de la persona (set) y el ambiente (setting) en la modulación de los efectos subjetivos y terapéuticos de sustancias como la psilocibina o el MDMA. El objetivo principal fue...

DOI: 10.53680/vertex.v37i171.978 (opens in new tab) Context archaeology Persona Perspective graphical Product mathematics +1

Severe Illness Associated with Eating Mushroom-Containing Chocolate Products — United States, January–October 2024

MMWR Morbidity and Mortality Weekly Report April 9, 2026 Jelonia T. Rumph, Andrea Winquist, Alyssa N. Troeschel et al.

In late spring 2024, CDC was alerted to an outbreak of poisoning potentially associated with eating Diamond Shruumz microdosing chocolate bars. Diamond Shruumz microdosing chocolate bars are edible products designed so that small doses of mushroom-derived psychoactive compounds and other psychoactive ingredients can be eaten in a presectioned serving. In response to this alert, CDC and the Food...

Altered States of Consciousness and the Subconscious Mind: A Comprehensive Comparative Review of Disciplines, Neurobiological Mechanisms, Clinical Applications, and Philosophical Frameworks — Including Life Between Lives and Transpersonal Hypnotherapy

Preprints.org April 7, 2026 Luis Miguel Gallardo preprint

Altered states of consciousness (ASC) represent a universal human capacity for accessing and transforming the subconscious mind, employed across cultures and millennia through diverse contemplative, somatic, pharmacological, ritual, and technological modalities. This comprehensive review synthesizes evidence from over 25 distinct disciplines spanning five clusters: (A) contemplative and...

Hallucinogenic Therapy in Alzheimer's Disease targeting Mitochondria-Associated Membranes.

Neuroscience April 6, 2026 Fernando Minauro-Sanmiguel, Hector Vargas-Perez

Mitochondrial dysfunction is increasingly recognized as a central driver of Alzheimer's disease (AD), contributing to neuroinflammation, synaptic failure, and energy collapse.Emerging preclinical evidence suggests that classic hallucinogens, such as psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), mescaline, may restore mitochondrial integrity by activating Serotonin...